

## A Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- recurrent or persistent endometrial carcinoma which has progressed or recurred after at least 1, but no more than 2, prior lines of therapy

---

**Exclusion Criteria:**

- primary invasive ovarian or cervical cancer occurring with this cancer - other cancer occurring in the past 5 years - active or history of autoimmune disease or immune deficiency - history of cardiac, respiratory or neurological conditions (study staff will review)

### Conditions & Interventions

**Interventions:**

Drug: Abemaciclib, Drug: Atezolizumab - 21 Day Cycle, Drug: Atezolizumab - 28 Day Cycle, Drug: Bevacizumab, Drug: Giredestrant, Drug: Inavolisib, Drug: Ipatasertib, Drug: Letrozole, Drug: Talazoparib, Drug: Tiragolumab, Drug: Trastuzumab emtansine

**Conditions:**

Cancer, Women's Health

**Keywords:**

Clinics and Surgery Center (CSC), EndoCA, Endometrial Cancer

### More Information

**Description:** The purpose of this study is to learn the effects, good or bad, of several possible study treatments for EndoCA that are selected based on genetic markers that can be found in these tumors.

**Study Contact:** Britt Erickson - bkeric@umn.edu

**Principal Investigator:** Britt Erickson

**Phase:** Phase 1/Phase 2

**IRB**

**Number:** SITE00001240

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.